| 204.7784 -1.472 (-0.71%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 248.24 | 1-year : | 289.95 |
| Resists | First : | 212.53 | Second : | 248.24 |
| Pivot price | 206.25  |
|||
| Supports | First : | 195.25 |
Second : | 184.57 |
| MAs | MA(5) : | 204.46 |
MA(20) : | 202.65 |
| MA(100) : | 190.56 |
MA(250) : | 184.12 |
|
| MACD | MACD : | 4 |
Signal : | 4.7 |
| %K %D | K(14,3) : | 56 |
D(3) : | 58.9 |
| RSI | RSI(14): 58.2 |
|||
| 52-week | High : | 212.53 | Low : | 153.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBH ] has closed above bottom band by 39.1%. Bollinger Bands are 0.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 208.77 - 209.97 | 209.97 - 211.05 |
| Low: | 201.48 - 202.78 | 202.78 - 203.96 |
| Close: | 202.91 - 204.99 | 204.99 - 206.87 |
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Tue, 14 Jul 2026
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? - The Motley Fool
Tue, 14 Jul 2026
BBH ETF Profile: Dividends, Returns (BOATS:BBH) - TradingView
Tue, 14 Jul 2026
BBH ETF Profile: Dividends, Returns (NASDAQ:BBH) - TradingView
Sat, 11 Jul 2026
Which is the Better Choice for Healthcare Investors? IYH or BBH? - The Motley Fool
Sat, 11 Jul 2026
Which is the Better Choice for Healthcare Investors? IYH or BBH? - The Globe and Mail
Thu, 09 Jul 2026
BBH Should I Buy - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|